Healthcare
Live Price
Offline$0.632
+5.33% today
1Y Change
-2.92%
Window
Jun 26, 2025 โ Jun 18, 2026
Coverage: 246 bars ยท Jun 26, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Context Therapeutics Inc. (CNTX) is a Healthcare stock with a market cap of $220.00M and listed on NASDAQ. The stock last traded around $0.63 and down 2.9% across the available one-year price window (Jun 26, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +17.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +17.4%, free cash flow +9.9% with operating margin 0.0% and ROIC -65.5%. Stock Foundry combines CNTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +17.4%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.2% over the next 5 trading days and finished higher after 1 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -3.3% | -2.1% | -15.8% |
2026 Mar 19, 2026 | -27.3% | -3.7% | -15.1% | -18.7% |
2025 Nov 5, 2025 | -11.1% | -5.3% | +4.4% | -8.8% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CNTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CNTX Max Drawdown
-82.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CNTX and SPY.
Company Overview
Context Therapeutics Inc.
NASDAQ
Context Therapeutics Inc. is a biopharmaceutical company focused on advancing treatments for hormone-driven female cancers. Primarily, the company develops investigational therapies targeting estrogen receptors, aiming to innovate in areas of significant unmet medical need. Context Therapeutics operates within the life sciences and biotechnology sectors, engaging in research and development to combat cancers like breast and ovarian cancer. The company's approach involves optimizing therapeutic outcomes through cutting-edge research, clinical trials, and strategic collaborations. With a strong commitment to patient-centered care, Context Therapeutics impacts the healthcare industry by striving to provide more effective and personalized treatment options for female cancer patients. Established in an era of increased focus on women's health, Context Therapeutics plays a vital role in the continued evolution and enhancement of oncology treatment solutions in the financial market.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.